Paper18752004
Vascular targeted therapies in oncology.
Siemann DW and 1 other. Cell Tissue Res, 2009. Cited by 72 papers, by iCite.
Cite this record
ConductScience Library. Vascular targeted therapies in oncology. Papers, record 18752004. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/18752004
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiogenesis Inhibitors | Major topic |
| Neoplasms | Major topic |
| Neovascularization, Pathologic | Major topic |
| Animals | |
| Blood Vessels | |
| Cell Death | |
| Drug Delivery Systems | |
| Humans | |
| Oxygen |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA084408 | NCI NIH HHS | United States | R01CA084408 | PubMed and NIH | NIH RePORTER |
| R01 CA089655 | NCI NIH HHS | United States | R01CA089655 | PubMed and NIH | NIH RePORTER |
| CA084408 | NCI NIH HHS | United States | R01CA084408 | PubMed and NIH | NIH RePORTER |
| CA089655 | NCI NIH HHS | United States | R01CA089655 | PubMed and NIH | NIH RePORTER |
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9845119 | Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. | Int J Radiat Oncol Biol Phys | 1998 | https://conductscience.org/library/papers/9845119 | PubMed |
| 2 | 11173139 | In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. | Int J Radiat Oncol Biol Phys | 2001 | https://conductscience.org/library/papers/11173139 | PubMed |
| 3 | 15928673 | Disrupting tumour blood vessels. | Nat Rev Cancer | 2005 | https://conductscience.org/library/papers/15928673 | PubMed |
| 4 | 15254283 | Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. | N Engl J Med | 2004 | https://conductscience.org/library/papers/15254283 | PubMed |
| 5 | 15701823 | Differentiation and definition of vascular-targeted therapies. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/15701823 | PubMed |
| 6 | 15197790 | Vascular-targeting therapies for treatment of malignant disease. | Cancer | 2004 | https://conductscience.org/library/papers/15197790 | PubMed |
| 7 | 23484531 | An update on the clinical development of drugs to disable tumor vasculature. | Expert Opin Drug Discov | 2007 | https://conductscience.org/library/papers/23484531 | PubMed |
| 8 | 10466764 | Tumour vasculature as a target for cancer therapy. | Br J Cancer | 1999 | https://conductscience.org/library/papers/10466764 | PubMed |
| 9 | 15474333 | Therapeutic strategies that selectively target and disrupt established tumor vasculature. | Hematol Oncol Clin North Am | 2004 | https://conductscience.org/library/papers/15474333 | PubMed |
| 10 | 16551862 | 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16551862 | PubMed |
| 11 | 16818709 | Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16818709 | PubMed |
| 12 | 12060643 | Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. | Clin Cancer Res | 2002 | https://conductscience.org/library/papers/12060643 | PubMed |
| 13 | 12778131 | Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/12778131 | PubMed |
| 14 | 14760060 | Vascular targeting agents as cancer therapeutics. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/14760060 | PubMed |
| 15 | 16224539 | Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. | J Clin Invest | 2005 | https://conductscience.org/library/papers/16224539 | PubMed |
| 16 | 12635171 | Specialization of tumour vasculature. | Nat Rev Cancer | 2002 | https://conductscience.org/library/papers/12635171 | PubMed |
| 17 | 12067983 | A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. | Cancer Res | 2002 | https://conductscience.org/library/papers/12067983 | PubMed |
| 18 | 12516034 | Role of angiogenesis in tumor growth and metastasis. | Semin Oncol | 2002 | https://conductscience.org/library/papers/12516034 | PubMed |
| 19 | 12499266 | ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. | Cancer Res | 2002 | https://conductscience.org/library/papers/12499266 | PubMed |
| 20 | 895546 | Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. | Microvasc Res | 1977 | https://conductscience.org/library/papers/895546 | PubMed |
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42828053 | Fibrinogen-Drug Nanoparticles Achieve Durable Responses in Pancreatic and Breast Cancer Murine Models. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/42828053 | PubMed |
| 40529069 | Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization. | ACS Med Chem Lett | 2025 | https://conductscience.org/library/papers/40529069 | PubMed |
| 39776800 | Vascularized tumor on a microfluidic chip to study mechanisms promoting tumor neovascularization and vascular targeted therapies. | Theranostics | 2025 | https://conductscience.org/library/papers/39776800 | PubMed |
| 39125647 | Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39125647 | PubMed |
| 37874534 | Targeting circulating tumor cells to prevent metastases. | Hum Cell | 2024 | https://conductscience.org/library/papers/37874534 | PubMed |
| 35935920 | Synthesis of a boron-containing amidoxime reagent and its application to synthesize functionalized oxadiazole and quinazolinone derivatives. | Tetrahedron Lett | 2022 | https://conductscience.org/library/papers/35935920 | PubMed |
| 35769106 | 3D-Cultured Vascular-Like Networks Enable Validation of Vascular Disruption Properties of Drugs In Vitro. | Front Bioeng Biotechnol | 2022 | https://conductscience.org/library/papers/35769106 | PubMed |
| 32706818 | Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption. | PLoS One | 2020 | https://conductscience.org/library/papers/32706818 | PubMed |
| 32130518 | High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenetic effect by an action similar to VEGF. | Acta Diabetol | 2020 | https://conductscience.org/library/papers/32130518 | PubMed |
| 31799244 | Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 mAb and Its Efficacy Assessments by Molecular Imaging. | Front Bioeng Biotechnol | 2019 | https://conductscience.org/library/papers/31799244 | PubMed |
| 31676822 | Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery. | Sci Rep | 2019 | https://conductscience.org/library/papers/31676822 | PubMed |
| 31551349 | Longitudinal Photoacoustic Imaging of the Pharmacodynamic Effect of Vascular Targeted Therapy on Tumors. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31551349 | PubMed |
| 29983002 | Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters. | Cancer Med | 2018 | https://conductscience.org/library/papers/29983002 | PubMed |
| 28628642 | Nanoscale quantification of the biophysical characterization of combretastatin A-4-treated tumor cells using atomic force microscopy. | PLoS One | 2017 | https://conductscience.org/library/papers/28628642 | PubMed |
| 27347765 | Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats. | Radiology | 2016 | https://conductscience.org/library/papers/27347765 | PubMed |
| 26983987 | The impact of hypoxia and its modification of the outcome of radiotherapy. | J Radiat Res | 2016 | https://conductscience.org/library/papers/26983987 | PubMed |
| 26745936 | Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy. | Med Phys | 2016 | https://conductscience.org/library/papers/26745936 | PubMed |
| 26700713 | Roadmap to Clinical Use of Gold Nanoparticles for Radiation Sensitization. | Int J Radiat Oncol Biol Phys | 2016 | https://conductscience.org/library/papers/26700713 | PubMed |
| 26418302 | Nanoparticle Mediated Tumor Vascular Disruption: A Novel Strategy in Radiation Therapy. | Nano Lett | 2015 | https://conductscience.org/library/papers/26418302 | PubMed |
| 26325604 | The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts. | Cancer Lett | 2015 | https://conductscience.org/library/papers/26325604 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CDH5 | 1003 | PubTator's text mining | https://conductscience.org/library/genes/1003 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/18752004
GET https://conductscience.org/api/papers/v1/18752004/references?page=2